




RealRate

PHARMACEUTICAL 2021

Unique N V
Rank 164 of 394

uniQure



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Unique N V are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Unique N V compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 38% points. The greatest weakness of Unique N V is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 45% points.

The company's Economic Capital Ratio, given in the ranking table, is 296%, being 39% points above the market average of 256%.

Input Variable	Value in 1000 USD
Assets, Current	258,911
Cost of Goods Sold	0
Intangible Assets	3,903
Liabilities, Current	27,334
Liabilities, Non-Current	69,156
Other Assets	45,253
Other Compr. Net Income	16,596
Other Expenses	-11,292
Other Liabilities	0
Other Net Income	-12,192
Other Revenues	40,856
Property and Equipment	32,328
Research and Development	122,400
Selling, General and Administrative Expense	42,580

Output Variable	Value in 1000 USD
Assets	340,395
Liabilities	96,490
Expenses	153,688
Revenues	40,856
Stockholders Equity	243,905
Net Income	-125,024
Comprehensive Net Income	-116,726
BaseVar	330,108
ECR before Limited Liability	190%
Economic Capital Ratio	296%